12 Best Slow Growth Stocks to Invest In
On the night of November 27, during a week cut by Thanksgiving, stock futures saw minimal movement, with the Nasdaq Composite poised to end a seven-month winning run.
Abbott Laboratories (ABT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 12,032,884 | $1,611,684,674 | +2% | 0.58% |
| 2. | Diamond Hill Capital Ric Dillon | 5,603,583 | $750,543,907 | -6% | 3.56% |
| 3. | Adage Capital Management Phill Gross And Robert Atchinson | 2,296,987 | $307,658,439 | +44% | 0.49% |
| 4. | 1,876,200 | $251,298,228 | -12% | 0.04% | |
| 5. | Alyeska Investment Group Anand Parekh | 1,273,671 | $170,595,494 | -12% | 0.52% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $122.50 | 2,040 | $249,900.00 | 7,296 | 2021-02-23 | Filing | |
| $73.40 | 2,000 | $146,798.20 | 52,562 | 2019-04-22 | Filing | |
| $72.32 | 100 | $7,231.50 | 6,400 | 2019-01-31 | Filing | |
| $72.31 | 100 | $7,230.50 | 6,300 | 2019-01-31 | Filing | |
| $72.33 | 1,800 | $130,194.00 | 6,200 | 2019-01-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $128.02 | 1,586 | $203,042.57 | 30,384 | 2025-11-25 | Filing | |
| $134.55 | 5,550 | $746,758.05 | 51,003 | 2025-08-08 | Filing | |
| $129.66 | 2,600 | $337,116.00 | 34,058 | 2025-04-30 | Filing | |
| $136.65 | 200 | $27,329.00 | 71,928 | 2025-03-07 | Filing | |
| $133.82 | 91,167 | $12,199,967.94 | 71,928 | 2025-03-06 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 173,154,308 | $23,192,288,014 | 0.35% | |
| 2. | 141,559,956 | $18,960,540,594 | 0.33% | |
| 3. | 78,225,991 | $10,477,589,235 | 0.36% | |
| 4. | 61,614,739 | $8,251,973,846 | 1.33% | |
| 5. | 38,768,839 | $5,192,680,251 | 0.97% |
News See All
Abbott's (ABT) Exact Sciences Deal is "Very, Very Important," Says Jim Cramer
This show marked more than a month after Cramer discussed pharmaceuticals and diagnostics devices firm Abbott Laboratories (NYSE:ABT).
11 Stocks Jim Cramer Recently Offered Insights On
“Look, we knew it had gotten harder since November began, right? But this hard? Wow.
10 Stocks Jim Cramer Talked About
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed areas of the market that he wanted to see money move out of.
Here’s Why Abbott Laboratories (ABT) Traded Down in Q3
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Citi Reaffirms Buy Rating on Abbott (ABT) Following Favorable Court Ruling
On October 24, Citi analyst Joanne Wuensch reaffirmed a Buy rating on Abbott Laboratories (NYSE:ABT), as reported by The Fly.
15 Best Dividend Growth Stocks to Buy Now
Dividends are a way for companies to share a portion of their profits with investors. Each share of stock entitles its holder to a specific dividend payment.
Abbott Laboratories (ABT) Rated Buy as Benchmark Highlights Diagnostics Growth and Global Resilience
Abbott Laboratories (NYSE:ABT) ranks among the best medical device stocks to invest in.
12 Best Medical Device Stocks to Invest In Now
As chronic diseases like diabetes and cancer become more common, medical device technology is becoming increasingly innovative.
Abbott Laboratories (NYSE:ABT) Q3 2025 Earnings Call Transcript
Operator: Good morning, and thank you for standing by. Welcome to Abbott Laboratories' Third Quarter 2025 Earnings Conference Call.